Pharma Pulse 9/5/24: Legal Advice for DSCSA Compliance Teams, Pharmacy Students Discuss Learning Through Social Media Platforms & more

HDA 2024 Traceability Seminar: Legal Advice for DSCSA Compliance Teams

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, highlights the hard-hitting points that she anticipated will be covered during her session at the 2024 HDA Traceability Seminar.

Pharmacy Students Discuss Learning Through Social Media Platforms

Alessia Reeves, Dylan LeBoeuf, and Taylor Hurst, all PharmD candidates from the University of Louisiana Monroe, discuss how leveraging social media platforms to supplement their traditional classroom learning. They describe using TikTok, Instagram, and YouTube to find concise summaries of course topics, interactive explanations of complex disease processes, and even daily practice questions to prepare for the NAPLEX exam.

FDA Wants Safer Cancer Drugs, but Some Startups Fear Unintended Consequences

Companies developing cancer drugs wrestle with ‘Project Optimus’

Viz.ai and ALCMI Partner to Unite AI and Lung Cancer Research Communities

Viz.ai announced a partnership with the Addario Lung Cancer Medical Institute (ALCMI), an international consortium made up of 25 of the world’s premier lung cancer research institutions. Together, Viz.ai and ALCMI will collaborate on improving lung cancer outcomes in patients by focusing on early detection with improved clinical workflow for nodule workup through to precision medicine optimization.

Andrew Cournoyer on LinkedIn

Innovative thinking is required to help patients get access to life changing medications and payers are at the core of this decision-making process. Unfortunately, they lack a seat at the table when it comes to manufacturer clinical trial design and evidence generation. Check out this article in Pharmaceutical Executive where I had the pleasure of collaborating with Doug Fulling to highlight how establishing payer-drug manufacturer partnerships early within the clinical development process could possibly alleviate downstream access obstacles.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs